Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.

about

Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.

Item

http://www.wikidata.org/entity/Q55447998

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.

@en

Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.

@nl

type

Item

label

Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.

@en

Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.

@nl

prefLabel

Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.

@en

Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.

@nl

P1476

Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.

@en

P2093

Douae Bensaid

http://www.w3.org/2001/XMLSchema#string

Marc Grégoire

http://www.w3.org/2001/XMLSchema#string

Mohammed Errami

http://www.w3.org/2001/XMLSchema#string

Philippe Bertrand

http://www.w3.org/2001/XMLSchema#string

Sophie Deshayes

http://www.w3.org/2001/XMLSchema#string

Thibaut Blondy

http://www.w3.org/2001/XMLSchema#string

Virginie Dehame

http://www.w3.org/2001/XMLSchema#string

P2860

Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province

Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers

PD-L1 expression in human cancers and its association with clinical outcomes

Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

Epigenetic control of the foxp3 locus in regulatory T cells

A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.

A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.

The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells

New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.

P2888

s13148-018-0517-9

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13148-018-0517-9

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christophe Blanquart

P577

2018-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104899804

http://www.w3.org/2001/XMLSchema#string

P698

29946373

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

6006850

http://www.w3.org/2001/XMLSchema#string